Table 3.
Treatments | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Parameters | Control | A10 | A20 | A30 | A40 | A50 | ALN10 | ALN20 | ALN30 | ALN40 | ALN 50 | SEM |
TM (%) | 50.1b | 52.3c | 56.5b | 59.8b | 54.3b | 41.2c | 53.4b | 60.1b | 72.1a | 56.3b | 45.2b,c | 2.1 |
PM (%) | 17.1c | 20.2b,c | 24.3b | 27.4a,b | 23.7b,c | 16.4c | 25.7a,b | 27.9a,b | 33.2a | 26.3a,b | 16.5c | 1.3 |
VAP (μm/s) | 30.4 | 33.4 | 34.2 | 34.7 | 32.4 | 29.3 | 34.7 | 35.2 | 36.9 | 34.5 | 29.8 | 2.5 |
VSL (μm/s) | 16.7b | 17.4b | 19.3a,b | 20.1a,b | 18.3a | 16.2b | 18.5a,b | 20.6a,b | 24.3a | 20.1a,b | 16.4b | 1.7 |
VCL (μm/s) | 53.2 | 54.1 | 55.3 | 56.2 | 53.8 | 51.0 | 54.7 | 55.5 | 57.1 | 54.0 | 51.8 | 2.3 |
LIN (%) | 31.4b | 32.5b | 35.0a,b | 35.9a,b | 33.9a,b | 31.3b | 33.9a,b | 36.2a | 42.5a | 36.1a,b | 31.4b | 2.1 |
Different superscripts within the same row indicate significant differences among groups (P < 0.05).
Extender supplemented with different levels of alpha-lipoic acid containing 10 (A10), 20 (A20), 30 (A30), 40 (A40), and 50 (A50) μM and alpha-lipoic acid loaded nanostructured lipid carriers (ALN) containing 10 (ALN10), 20 (ALN20), 30 (ALN30), 40 (ALN40), and 50 (ALN50) μM.
Abbreviations: LIN, linearity; PM, progressive motility; TM, total motility; VSL, straight-line velocity; VAP, average path velocity; VCL, curvilinear velocity.